Our range of precision engineered cascade impactors measure the size distribution (particle size) of inhaled drug products, providing critical information about where particles in aerosol clouds are likely to be deposited in the lungs following inhalation.
Better in vitro – in vivo correlation (IVIVC) has long been an industry aim. This is particularly difficult in the case of inhaled and nasal products because of the complications involved in precisely correlating drug deposition behaviour with clinical efficacy, the impact of patient-to-patient variability and the complex interaction between formulation and device.
One strategy for improving the significance of cascade impaction data is to modify the test set-up in order to mimic the in vivo drug delivery process more closely.
The drug mass sized by the cascade impactor (impactor sized mass) should ideally be representative of the dose that would actually enter the lungs. To achieve this, the induction port or other accessory used to interface the device to the impactor must capture a representative fraction of the dose. Our throat and nasal models have a standardised internal geometry more representative of in vivo physiology than a standard induction port and suitable for a range of patient profiles.
We offer a range of training courses, presentations and seminars covering a wide range of topics.Find out More
A comprehensive range of both in-house and on-site product servicing options are availableFind out More
28 April 2022; Nottingham, UK: Copley Scientific, the global leader in inhaled product testing equipment, has launched...Find out More
26 October 2021; Nottingham, UK: The latest accessory from Copley Scientific, the global leader in inhaled product...Find out More
23 June 2021; Nottingham, UK: Copley Scientific has joined the Industries Forum of the Taskforce for Lung Health....Find out More